tldrdaily.news logo
Tag

Pancreatic Cancer

All articles tagged with #pancreatic cancer

MYC’s RNA Trick Drives Immune Evasion in Pancreatic Cancer
science3 days ago

MYC’s RNA Trick Drives Immune Evasion in Pancreatic Cancer

Researchers identify a mechanism where the MYC protein shifts from DNA to nascent RNA under stress, using an RNA-binding region (RBRIII) to promote multimerization and recruit the nuclear exosome to degrade RNA at R-loops, thereby suppressing innate immune signaling (via TLR3 and TBK1) in pancreatic cancer. Mutating the RNA-binding region prevents this immune suppression and causes tumor regression in immunocompetent mice, suggesting therapies that block MYC’s RNA-binding function could expose tumors to immune attack while preserving MYC’s transcriptional activity.

via Indian Defence Review|
#innate-immunity#myc-oncoprotein#pancreatic-cancer
FDA Approves Wearable TTFields Therapy for Locally Advanced Pancreatic Cancer
health4 days ago

FDA Approves Wearable TTFields Therapy for Locally Advanced Pancreatic Cancer

The FDA approved Optune Pax, a wearable device delivering abdominal tumor treating fields (TTFields) to treat locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, based on PANOVA-3 which showed longer median overall survival and pain-free survival with TTFields versus chemotherapy alone; skin reactions were common; the device costs about $21,000 per month and includes patches, a generator, and support services.

via Medscape|
#fda-approval#health#novocure
Nerve-Fibroblast Loop Spurs Early Pancreatic Cancer Growth
health-and-medicine9 days ago

Nerve-Fibroblast Loop Spurs Early Pancreatic Cancer Growth

Researchers at Cold Spring Harbor Laboratory uncovered a self-sustaining loop in early pancreatic cancer: myCAFs (fibroblasts) lure sympathetic nerves, whose norepinephrine signals activate the fibroblasts and recruit more nerves, accelerating tumor development. Blocking nerve activity slowed growth by about 50% in mice/human cell experiments, pointing to therapies that disrupt the nerve–fibroblast crosstalk alongside existing cancer treatments.

via ScienceDaily|
#health-and-medicine#mycafs#nervous-system
Surge in pancreatic cancer among younger adults prompts call for quick detection and lifestyle tweaks
health11 days ago

Surge in pancreatic cancer among younger adults prompts call for quick detection and lifestyle tweaks

Pancreatic cancer, long seen as a disease of older people, is increasingly diagnosed in people in their 30s–50s as obesity and metabolic disease rise; doctors warn that its early signs are vague and often dismissed, contributing to diagnoses only after the cancer has spread in about 80% of cases, with five-year survival around 12%. The piece highlights rising incidence among younger patients, the role of risk factors like smoking, obesity, and genetics (BRCA/ATM), and new research on epigenetic changes in genes such as KLF5 that may fuel growth. It also offers lifestyle prevention tips—limiting red/processed meats and ultra-processed foods, cooking at home, eating lean proteins, and considering environmental exposures like pesticides—and notes advances in treatment (robotic Whipple surgeries, BRCA-targeted therapies) that improve outcomes when detected early.

via Daily Mail|
#early-signs#health#pancreatic-cancer
Medico’s Mouse‑Only “Cure” Sparks Hype and Scrutiny Over Pancreatic Cancer Trial
science16 days ago

Medico’s Mouse‑Only “Cure” Sparks Hype and Scrutiny Over Pancreatic Cancer Trial

Spanish biochemist Mariano Barbacid announced a “cure” for pancreatic cancer based on a triple‑drug therapy that regression‑tested 45 mice; the work, published in PNAS after Nature declined to publish, has not been tested in humans or metastases. The flashy public rollout and patent push by Barbacid’s Vega Oncotargets drew patient inquiries and criticism from CNIO colleagues for overclaiming and conflicts of interest. Independent experts urge cautious optimism, noting the (promising but early) preclinical results and emphasizing that mouse outcomes rarely translate to human cures, with human trials years away and more work needed on safety and efficacy.

via EL PAÍS English|
#barbacid#kras#pancreatic-cancer
Four-marker blood test shows promise for early pancreatic cancer detection
health20 days ago

Four-marker blood test shows promise for early pancreatic cancer detection

A NIH-backed study reports a four-marker blood test—CA19-9, THBS2, ANPEP, and PIGR—that accurately detects pancreatic ductal adenocarcinoma, including early-stage disease, with 91.9% overall accuracy at a 5% false-positive rate and 87.5% sensitivity for stage I/II cancers; the test also differentiates cancer from pancreatitis and could enable screening for high-risk groups, though larger prediagnostic studies are needed.

via SciTechDaily|
#biomarkers#ca19-9#early-detection
Three-drug combo eliminates pancreatic tumors in mice, signaling potential human therapies
health26 days ago

Three-drug combo eliminates pancreatic tumors in mice, signaling potential human therapies

A triple-drug regimen that targets three cancer-growth pathways—KRAS, its related pathway, and STAT3—completely eradicated pancreatic tumors across three mouse models, prevented tumor recurrence for about seven months, and showed no significant toxicity in mice. The treatment uses afatinib, daraxonrasib, and a novel STAT3 inhibitor. While the results are promising, researchers caution that mouse findings may not translate to humans and plan further drug development and clinical testing across diverse KRAS mutations.

via Live Science|
#health#kras#mice-model
Triple KRAS Pathway Blockade Drives Complete Regression of Pancreatic Tumors in Preclinical Tests
science27 days ago

Triple KRAS Pathway Blockade Drives Complete Regression of Pancreatic Tumors in Preclinical Tests

Spanish researchers report a three-drug combo (RMC-6236/daraxonrasib, Afatinib, SD36) that simultaneously targets RAF1 (KRAS downstream), EGFR (upstream) and STAT3 signaling, producing complete regression of pancreatic tumors in orthotopic mouse models and patient-derived tissues with no resistance for more than 200 days, suggesting potential clinical trials for pancreatic ductal adenocarcinoma.

via Drug Target Review|
#kras#pancreatic-cancer#pdac
Triple-therapy breakthrough halts pancreatic tumors in mice
health28 days ago

Triple-therapy breakthrough halts pancreatic tumors in mice

Spanish CNIO researchers report that a triple combination therapy—an experimental KRAS inhibitor, an existing lung-cancer drug, and a protein degrader—caused long-lasting regression and prevented recurrence of pancreatic ductal adenocarcinoma in three mouse models, a potential path toward new clinical trials, though optimization for patients and trials is not yet planned.

via Euronews.com|
#cnio#health#kras
Stellate-Cell Periostin Sparks Early Nerve Invasion in Pancreatic Cancer
science1 month ago

Stellate-Cell Periostin Sparks Early Nerve Invasion in Pancreatic Cancer

Brazilian researchers identify periostin produced by pancreatic stellate cells as a key driver that remodels surrounding tissue, enabling pancreatic cancer cells to invade nerves early and spread, creating a dense desmoplastic microenvironment that hinders chemotherapy and immunotherapy; targeting periostin or the stellate cells offers a potential path for precision therapies to curb invasion and metastasis.

via SciTechDaily|
#pancreatic-cancer#perineural-invasion#periostin
Rob Hirst, Co-Founder and Drummer of Midnight Oil, Dies at 70
obituaries1 month ago

Rob Hirst, Co-Founder and Drummer of Midnight Oil, Dies at 70

Robert "Rob" Hirst, co-founder and founding drummer of Australian rock band Midnight Oil and a key co-writer of many of its songs, has died at 70 after a pancreatic cancer diagnosis in 2023. The band announced his death on social media, praising him as a brother and noting that his songs, including hits like "Beds Are Burning" and "The Dead Heart" (co-written with Garrett and Moginie), will live on as part of their legacy.

via Deadline|
#australian-rock#midnight-oil#obituaries